SeekGene specializes in single-cell sequencing and TCR-pMHC pairing technologies in understanding immune responses in the single-cell resolution to help screen, treat and monitor diseases.
SeekGene's Products & Differentiators
SeekOne® MM 单细胞转录组试剂盒是由北京寻因生物科技有限公司自主研发的高通量单细胞转录组建库试剂盒。该试剂盒无需配备昂贵仪器，即可完成从单细胞捕获到转录组文库构建全过程，同时配备单细胞数据分析软件（SeekOne® Tools），为您提供一站式单细胞转录组解决方案。
Expert Collections containing SeekGene
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
SeekGene is included in 1 Expert Collection, including Digital Health.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Latest SeekGene News
May 20, 2022
News provided by Share this article Share this article Big Memory Software Improves Data Loading and Exporting Performance by Two Orders of Magnitude; Enables SeekGene to Scale Up Analysis Throughput by Five Times MILPITAS, Calif., May 12, 2022 /PRNewswire/ -- MemVerge ™, the pioneers of Big Memory software, today announced that SeekGene, a biotechnology research firm focusing on single-cell technology, has significantly reduced processing time and cost for data intensive single-cell analysis tasks using MemVerge Memory Machine running on AliCloud i4p compute instances. As a result, SeekGene is seeing a five-fold increase in output per virtual machine (VM) in its analytical operations. In particular, the data loading and exporting performance of its single cell sequencing pipeline has improved by two orders of magnitude, and it has doubled the sample size of the dataset used in the analyses. SeekGene is a biotechnology enterprise focusing on single-cell technology that supports clinical diagnosis and development of precision medicine. The medical biopharmaceutical organization owns an exclusive microporous chip and water-in-oil dual technology platform and performs independent research and development of high throughput single-cell products, experiments, and full-chain services for bioinformatics analysis. SeekGene is seeing a five-fold increase in output per virtual machine (VM) in its analytical operations. SeekGene's SeekOne NGS single-cell library platform, the SeekGene Online automated online data analysis platform, and its proprietary droplet method and micropore method dual platform sequencing capabilities provide data analysis for international scientific researchers. The sequencing services are deployed on AliCloud. However, because analytical processes use expression data as high as hundreds of thousands of reads, sequencing analysis can fail on traditional VM instances due to insufficient memory. In addition, the export and loading process of temporary data on disk during sequencing tasks can also be extremely lengthy. Using MemVerge Memory Machine Cloud Edition software running on AliCloud i4p VM instances, which feature Intel Optane persistent memory (PMem), SeekGene is now able to use large memory resources with no change to its code. This allows SeekGene to double its sample size and enables up to five times more concurrent processes to run. Further, with MemVerge Memory Machine Cloud Edition, SeekGene is able to improve data loading and exporting performance by two orders of magnitude by eliminating the I/O bottleneck that is caused by disk reads and writes. Specifically: On a traditional VM instance which uses NVMe SSD to save temporary data, it takes over 15 minutes to store the dataset. By employing MemVerge Memory Machine snapshot technology, saving the data takes only 2.5 seconds. When compared to AliCloud ESC.g5, the previous AliCloud VM instance used by SeekGene, the AliCloud ECS.i4p, together with MemVerge Memory Machine technology, enables SeekGene to run five concurrent tasks, each with twice the size of the original dataset. "Using MemVerge Memory Machine, we are able to employ large memory resources in the cloud without refactoring our code, and eliminate the delay caused by storage I/O otherwise required in our pipelines," said Xingyong Ma, Co-founder and Chief Scientist of SeekGene. "As a result, we are able to cut our analytical time and costs significantly while optimizing our single-cell sequencing capabilities for researchers worldwide to promote faster development of precision medicine." "The SeekGene use case is a typical example of how biotechnology researchers can revolutionize their computational analyses by leveraging Big Memory technology in the cloud," said Jonathan Jiang, Chief Operating Officer, MemVerge. "These data intensive workloads can now be performed at record speeds and at dramatically lower cost. For the biotechnology industry, this can be a true gamechanger." MemVerge Memory Machine enables applications to utilize 100% of available memory capacity across multiple memory types with no code refactoring required, while providing new operational capabilities to memory-centric workloads. MemVerge Memory Machine Cloud Edition extends these benefits to cloud workloads, delivering memory virtualization, in-memory fault-tolerance and mobility services that organizations can easily add to their cloud infrastructure. Stateful, non-fault-tolerant, and long-running apps can now realize the promise of cloud agility and flexibility. More information on Memory Machine Cloud Edition is available here. About MemVerge MemVerge is pioneering Big Memory Computing for a multi-cloud world. Major gaps exist in today's cloud infrastructure for data-intensive high-performance applications. MemVerge® Memory Machine™ delivers software-defined, composable memory and intelligent memory service to bridge these gaps. As a software leader in the CXL ecosystem, MemVerge composable memory technology provisions, tiers, disaggregates, and pools heterogeneous memory to scale memory capacity and decrease memory cost. MemVerge ZeroIO™ in-memory snapshot services transparently checkpoint, clone, replicate, and restore running applications anytime, anywhere in a multi-cloud computing environment. Overall, Big Memory Computing technologies shorten time-to-results and are delivering unprecedented in-memory application availability and mobility for leading enterprises, research institutions and cloud service providers. MemVerge aims to democratize data-intensive compute for researchers, scientists, analysts and engineers around the world, and liberate all workloads to move in multi-cloud environments everywhere. To learn more about MemVerge, visit www.memverge.com . Memory Machine™ and Memory Machine ZeroIO™ are trademarks owned by MemVerge. Media Contacts:
SeekGene Frequently Asked Questions (FAQ)
When was SeekGene founded?
SeekGene was founded in 2015.
Where is SeekGene's headquarters?
SeekGene's headquarters is located at Building 1, Zone 1, 8 Life Science Parkway, Beijing.
What is SeekGene's latest funding round?
SeekGene's latest funding round is Series A.
How much did SeekGene raise?
SeekGene raised a total of $15.45M.
Who are the investors of SeekGene?
Investors of SeekGene include BioTrack Capital, CDBI Partners, Delian Capital and ZhenFund.
Who are SeekGene's competitors?
Competitors of SeekGene include 10X Genomics.
What products does SeekGene offer?
SeekGene's products include SeekOne® MM单细胞转录组建库试剂盒 and 2 more.
Compare SeekGene to Competitors
Singleron Biotechnologies operates as a biotechnology company. It focuses on applying single-cell analysis technologies. The company offers a comprehensive solution for single-cell multi-omics sequencing, which allows for novel approaches in clinical research and molecular diagnostics. Singleron primarily serves the healthcare industry, particularly in areas of clinical diagnosis, drug development, and health management. It was founded in 2018 and is based in Koln, Germany.
Algorithmic Biologics focuses on molecular diagnostics and discovery through technology in the biotech sector. Their main offerings include a software platform with molecular testing workflows to improve efficiency and accuracy, leveraging AI and molecular computing research. The company primarily serves the healthcare industry, particularly in the areas of genomics research and clinical diagnostics. It was founded in 2021 and is based in Bangaluru, India.
Singular Genomics (NASDAQ:OMIC) operates as a life science technology company. The company offers a range of products, including a benchtop genomic sequencer and multi-omics technologies, designed to empower researchers and clinicians with fast and accurate results. Singular Genomics primarily serves the research and medical sectors. It was founded in 2016 and is based in San Diego, California.
Akoya Biosciences (NASDAQ: AKYA) focuses on spatial biology within the biotechnology industry. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya primarily serves the needs of researchers across discovery, translational, and clinical research sectors. It was founded in 2015 and is based in Menlo Park, California.
10X Genomics (NASDAQ: TXG) is a life science technology company. It offers Chromium platform, which allows researchers to study the diversity of cells within a tissue or organ. The company's products are used by researchers to study the biology of cells, including gene expression, protein expression, and spatial organization. It was formerly known as Avente Biosystems. It was founded in 2012 and is based in Pleasanton, California.